153 related articles for article (PubMed ID: 29803689)
1. Fesoterodine: Pharmacological properties and clinical implications.
Gamé X; Peyronnet B; Cornu JN
Eur J Pharmacol; 2018 Aug; 833():155-157. PubMed ID: 29803689
[TBL] [Abstract][Full Text] [Related]
2. Fesoterodine clinical efficacy and safety for the treatment of overactive bladder in relation to patient profiles: a systematic review.
Chapple C; Oelke M; Kaplan SA; Scholfield D; Arumi D; Wagg AS
Curr Med Res Opin; 2015 Jun; 31(6):1201-43. PubMed ID: 25798911
[TBL] [Abstract][Full Text] [Related]
3. Fesoterodine for the treatment of overactive bladder.
Tzefos M; Dolder C; Olin JL
Ann Pharmacother; 2009 Dec; 43(12):1992-2000. PubMed ID: 19920160
[TBL] [Abstract][Full Text] [Related]
4. No. 353-Treatments for Overactive Bladder: Focus on Pharmacotherapy - An Addendum.
Geoffrion R
J Obstet Gynaecol Can; 2017 Dec; 39(12):1221-1229. PubMed ID: 28986184
[TBL] [Abstract][Full Text] [Related]
5. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome.
Michel MC
Expert Opin Pharmacother; 2008 Jul; 9(10):1787-96. PubMed ID: 18570610
[TBL] [Abstract][Full Text] [Related]
6. Tolterodine for the treatment of urge urinary incontinence.
Elterman DS; Chughtai B; Kaplan SA; Barkin J
Expert Opin Pharmacother; 2013 Oct; 14(14):1987-91. PubMed ID: 23885788
[TBL] [Abstract][Full Text] [Related]
7. Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review.
Gacci M; Novara G; De Nunzio C; Tubaro A; Schiavina R; Brunocilla E; Sebastianelli A; Salvi M; Oelke M; Gravas S; Carini M; Serni S
BMC Urol; 2014 Oct; 14():84. PubMed ID: 25348235
[TBL] [Abstract][Full Text] [Related]
8. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
[TBL] [Abstract][Full Text] [Related]
9. Review of the efficacy and safety of fesoterodine for treating overactive bladder and urgency urinary incontinence in elderly patients.
Wagg A; Oelke M; Angulo JC; Scholfield D; Arumi D
Drugs Aging; 2015 Feb; 32(2):103-25. PubMed ID: 25673122
[TBL] [Abstract][Full Text] [Related]
10. Fesoterodine fumarate.
Gomelsky A; Dmochowski RR
Drugs Today (Barc); 2010 Feb; 46(2):81-90. PubMed ID: 20393636
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
Cardozo L; Thorpe A; Warner J; Sidhu M
BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
[TBL] [Abstract][Full Text] [Related]
14. Safety and Tolerability of Fesoterodine in Older Adult Patients with Overactive Bladder.
Heesakkers J; Te Dorsthorst M; Wagg A
Can Geriatr J; 2022 Mar; 25(1):72-78. PubMed ID: 35310472
[TBL] [Abstract][Full Text] [Related]
15. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo.
Ney P; Pandita RK; Newgreen DT; Breidenbach A; Stöhr T; Andersson KE
BJU Int; 2008 Apr; 101(8):1036-42. PubMed ID: 18279452
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of antimuscarinic responders versus suboptimal responders in a randomized clinical trial of patients with overactive bladder symptoms.
Grenabo L; Herschorn S; Kaplan SA; Cardozo L; Scholfield D; Arumi D; Carlsson M; Chapman D; Ntanios F
Curr Med Res Opin; 2017 Oct; 33(10):1731-1736. PubMed ID: 28758802
[TBL] [Abstract][Full Text] [Related]
18. Economic impact of using fesoterodine for the treatment of overactive bladder with urge urinary incontinence in a vulnerable elderly population in the United States.
Qin L; Luo X; Zou KH; Snedecor SJ
J Med Econ; 2016; 19(3):229-35. PubMed ID: 26488196
[TBL] [Abstract][Full Text] [Related]
19. Review of fesoterodine.
Vella M; Cardozo L
Expert Opin Drug Saf; 2011 Sep; 10(5):805-8. PubMed ID: 21639817
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of fesoterodine fumarate for the treatment of an overactive bladder.
Mock S; Dmochowski RR
Expert Opin Drug Metab Toxicol; 2013 Dec; 9(12):1659-66. PubMed ID: 24205892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
